Previous 10 | Next 10 |
2024-02-23 14:08:15 ET More on Genmab Genmab: Recent Updates Support The Growth Narrative Genmab A/S (GMAB) Q4 2023 Earnings Call Transcript Genmab's Arbitration Loss: Best To Forgive And Forget (Rating Upgrade) Genmab reports FY results Genmab FY 202...
2024-02-21 03:44:55 ET Summary Genmab's 2023 annual report shows strong financial performance and continued clinical success, setting the company up for growth in 2024. The company's pipeline includes promising candidates and collaborations with industry giants, supporting future ...
2024-02-20 17:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-14 16:17:11 ET Genmab A/S (GMAB) Q4 2023 Results Conference Call February 14, 2024 12:00 PM ET Company Participants Jan van de Winkel - Co-Founder, President and Chief Executive Officer Anthony Mancini - Executive Vice President & COO Anthony Pagano -...
2024-02-14 12:59:28 ET More on Genmab Genmab's Arbitration Loss: Best To Forgive And Forget (Rating Upgrade) Genmab: 3 Trends To Track For A Strong 2024 And Beyond Genmab reports FY results Genmab FY 2023 Earnings Preview Seeking Alpha’s Quant ...
2024-02-14 11:29:41 ET More on Genmab Genmab's Arbitration Loss: Best To Forgive And Forget (Rating Upgrade) Genmab: 3 Trends To Track For A Strong 2024 And Beyond Genmab FY 2023 Earnings Preview Pfizer-Genmab cervical cancer drug gets accepted for EU review ...
Company Announcement COPENHAGEN, Denmark; February 14, 2024 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2023. Below is a summary of business progress in 2023, financial performance for the year and the financial outlook for...
Owens Corning Inc New (OC) is expected to report $2.82 for Q4 2023 Getty Realty Corporation (GTY) is expected to report $0.56 for Q4 2023 Bion Environmental Technologies Inc. (BNET) is expected to report for Q2 2024 Nexien BioPharma Inc (NXEN) is expected to report for Q2 2024 Ayt...
2024-02-13 11:11:35 ET More on Genmab Genmab's Arbitration Loss: Best To Forgive And Forget (Rating Upgrade) Genmab: 3 Trends To Track For A Strong 2024 And Beyond Pfizer-Genmab cervical cancer drug gets accepted for EU review Johnson & Johnson wins arbit...
2024-02-02 07:13:49 ET More on Genmab, Pfizer, etc. Pfizer Is Down 54% From Highs, Now Yields 6.1% Pfizer: Reviewing Q4 Earnings, FY24 Guidance - Why I Disagree With The Market Pfizer Inc. (PFE) Q4 2023 Earnings Call Transcript U.S. govt. opens bids in Medica...
News, Short Squeeze, Breakout and More Instantly...
Genmab A/S Company Name:
GMAB Stock Symbol:
NYSE Market:
2024-06-04 10:00:04 ET Asthika Goonewardene from Truist Financial issued a price target of $53.00 for GMAB on 2024-06-04 08:14:00. The adjusted price target was set to $53.00. At the time of the announcement, GMAB was trading at $28.83. The overall price target consensus...
Results from innovaTV207 evaluating tisotumab vedotin, showing 32.5% confirmed objective response rate in patients with recurrent or metastatic HNSCC, presented in a rapid oral session at 2024 ASCO ® Annual Meeting HNSCC is the sixth most common cancer worldwide, with inciden...
Preliminary analysis of data from the EPCORE™ NHL-2 study demonstrates patients with previously untreated follicular lymphoma (FL) who received epcoritamab in combination with rituximab-lenalidomide (R 2 ) experienced a 95% overall response rate (ORR) Results from the optimizat...